Literature DB >> 25427889

The Role of Oxidative Stress in Diabetic Neuropathy: Generation of Free Radical Species in the Glycation Reaction and Gene Polymorphisms Encoding Antioxidant Enzymes to Genetic Susceptibility to Diabetic Neuropathy in Population of Type I Diabetic Patients.

Mark A Babizhayev1,2,3, Igor A Strokov4, Valery V Nosikov5, Ekaterina L Savel'yeva6, Vladimir F Sitnikov6, Yegor E Yegorov7,8, Vadim Z Lankin9.   

Abstract

Diabetic neuropathy (DN) represents the main cause of morbidity and mortality among diabetic patients. Clinical data support the conclusion that the severity of DN is related to the frequency and duration of hyperglycemic periods. The presented experimental and clinical evidences propose that changes in cellular function resulting in oxidative stress act as a leading factor in the development and progression of DN. Hyperglycemia- and dyslipidemia-driven oxidative stress is a major contributor, enhanced by advanced glycation end product (AGE) formation and polyol pathway activation. There are several polymorphous pathways that lead to oxidative stress in the peripheral nervous system in chronic hyperglycemia. This article demonstrates the origin of oxidative stress derived from glycation reactions and genetic variations within the antioxidant genes which could be implicated in the pathogenesis of DN. In the diabetic state, unchecked superoxide accumulation and resultant increases in polyol pathway activity, AGEs accumulation, protein kinase C activity, and hexosamine flux trigger a feed-forward system of progressive cellular dysfunction. In nerve, this confluence of metabolic and vascular disturbances leads to impaired neural function and loss of neurotrophic support, and over the long term, can mediate apoptosis of neurons and Schwann cells, the glial cells of the peripheral nervous system. In this article, we consider AGE-mediated reactive oxygen species (ROS) generation as a pathogenesis factor in the development of DN. It is likely that oxidative modification of proteins and other biomolecules might be the consequence of local generation of superoxide on the interaction of the residues of L-lysine (and probably other amino acids) with α-ketoaldehydes. This phenomenon of non-enzymatic superoxide generation might be an element of autocatalytic intensification of pathophysiological action of carbonyl stress. Glyoxal and methylglyoxal formed during metabolic pathway are detoxified by the glyoxalase system with reduced glutathione as co-factor. The concentration of reduced glutathione may be decreased by oxidative stress and by decreased in situ glutathione reductase activity in diabetes mellitus. Genetic variations within the antioxidant genes therefore could be implicated in the pathogenesis of DN. In this work, the supporting data about the association between the -262T > C polymorphism of the catalase (CAT) gene and DN were shown. The -262TT genotype of the CAT gene was significantly associated with higher erythrocyte catalase activity in blood of DN patients compared to the -262CC genotype (17.8 ± 2.7 × 10(4) IU/g Hb vs. 13.5 ± 3.2 × 10(4) IU/g Hb, P = 0.0022). The role of these factors in the development of diabetic complications and the prospective prevention of DN by supplementation in formulations of transglycating imidazole-containing peptide-based antioxidants (non-hydrolyzed carnosine, carcinine, n-acetylcarcinine) scavenging ROS in the glycation reaction, modifying the activity of enzymic and non-enzymic antioxidant defenses that participate in metabolic processes with ability of controlling at transcriptional levels the differential expression of several genes encoding antioxidant enzymes inherent to DN in Type I Diabetic patients, now deserve investigation.

Entities:  

Keywords:  Advanced glycation Maillard reaction; Catalase promoter polymorphisms; Diabetic neuropathy; Gene encoding glutathione S-transferase; Glutathione; Imidazole-based Dipeptide Mimetics; Superoxide anion radical production; Therapeutic treatment of diabetic neuropathy; α-Dicarbonyl compounds

Mesh:

Substances:

Year:  2015        PMID: 25427889     DOI: 10.1007/s12013-014-0365-y

Source DB:  PubMed          Journal:  Cell Biochem Biophys        ISSN: 1085-9195            Impact factor:   2.194


  33 in total

1.  Upregulation of miR-133a-3p in the Sciatic Nerve Contributes to Neuropathic Pain Development.

Authors:  Lin-Li Chang; Hung-Chen Wang; Kuang-Yi Tseng; Miao-Pei Su; Jaw-Yuan Wang; Yi-Ta Chuang; Yi-Hsuan Wang; Kuang-I Cheng
Journal:  Mol Neurobiol       Date:  2020-07-06       Impact factor: 5.590

Review 2.  Corneal alteration and pathogenesis in diabetes mellitus.

Authors:  Han Zhao; Yan He; Yue-Rong Ren; Bai-Hua Chen
Journal:  Int J Ophthalmol       Date:  2019-12-18       Impact factor: 1.779

Review 3.  Schwann cell interactions with axons and microvessels in diabetic neuropathy.

Authors:  Nádia P Gonçalves; Christian B Vægter; Henning Andersen; Leif Østergaard; Nigel A Calcutt; Troels S Jensen
Journal:  Nat Rev Neurol       Date:  2017-01-30       Impact factor: 42.937

4.  Assessment of In Vitro Tests as Predictors of the Antioxidant Effects of Insulin, Metformin, and Taurine in the Brain of Diabetic Rats.

Authors:  George J Clark; Kashyap Pandya; Cesar A Lau-Cam
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 3.650

5.  A Novel Algorithm for the Evaluation of Corneal Nerve Beadings by in vivo Confocal Microscopy in Patients With Type 1 Diabetes Mellitus.

Authors:  Irene Abicca; Daniela Giannini; Marta Gilardi; Anna Maria Roszkowska; Mariacristina Parravano; Fabiana Picconi; Simona Frontoni; Domenico Schiano-Lomoriello
Journal:  Front Med (Lausanne)       Date:  2022-05-12

6.  A Clinical Trial about a Food Supplement Containing α-Lipoic Acid on Oxidative Stress Markers in Type 2 Diabetic Patients.

Authors:  Giuseppe Derosa; Angela D'Angelo; Davide Romano; Pamela Maffioli
Journal:  Int J Mol Sci       Date:  2016-10-28       Impact factor: 5.923

7.  Ethoxyquin is neuroprotective and partially prevents somatic and autonomic neuropathy in db/db mouse model of type 2 diabetes.

Authors:  Ying Liu; Yuan Sun; Osefame Ewaleifoh; Josh Wei; Ruifa Mi; Jing Zhu; Ahmet Hoke; Michael Polydefkis
Journal:  Sci Rep       Date:  2021-05-24       Impact factor: 4.379

8.  The In Vitro α-Glucosidase Inhibition Activity of Various Solvent Fractions of Tamarix dioica and 1H-NMR Based Metabolite Identification and Molecular Docking Analysis.

Authors:  Aamir Niaz; Ahmad Adnan; Rashida Bashir; Muhammad Waseem Mumtaz; Syed Ali Raza; Umer Rashid; Chin Ping Tan; Tai Boon Tan
Journal:  Plants (Basel)       Date:  2021-06-02

Review 9.  Current Advances in the Biochemical and Physiological Aspects of the Treatment of Type 2 Diabetes Mellitus with Thiazolidinediones.

Authors:  D Alemán-González-Duhart; F Tamay-Cach; S Álvarez-Almazán; J E Mendieta-Wejebe
Journal:  PPAR Res       Date:  2016-05-23       Impact factor: 4.964

10.  Epalrestat protects against diabetic peripheral neuropathy by alleviating oxidative stress and inhibiting polyol pathway.

Authors:  Qing-Rong Li; Zhuo Wang; Wei Zhou; Shou-Rui Fan; Run Ma; Li Xue; Lu Yang; Ya-Shan Li; Hong-Li Tan; Qing-Hua Shao; Hong-Ying Yang
Journal:  Neural Regen Res       Date:  2016-02       Impact factor: 5.135

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.